4/A: Lyra Therapeutics CEO Corrects Stock Option Filing
Amendment to Beneficial Ownership Statement
Lyra Therapeutics' President & CEO, Maria Palasis, filed an amended Form 4 to correct an erroneous report of stock option acquisition, confirming no beneficial ownership of the previously reported performance stock options.
Summary
- Maria Palasis, President & CEO and Director of Lyra Therapeutics, Inc., filed a Form 4/A to amend a previous filing.
- This amendment corrects an inadvertently filed Form 4 on October 3, 2025, which erroneously reported the acquisition of 3,667 Performance Stock Options (PSOs).
- Maria Palasis did not, in fact, acquire these PSOs.
- The PSOs, originally granted on March 21, 2024, for an aggregate of up to 11,000 shares of common stock (or 550,000 shares on a pre-split basis), were forfeited in their entirety by Maria Palasis on February 14, 2025, for no value.
- As of the date of this amendment, Maria Palasis does not beneficially own any of the PSOs granted on March 21, 2024.
Sentiment
Score: 5
Explanation: The filing corrects an administrative error, which is a neutral event for the company's operational or financial performance. While the initial error is a minor negative, the correction demonstrates transparency. The underlying forfeiture of options for no value is a negative for the executive, but this event occurred prior to the erroneous filing and its correction.
Positives
- The company and reporting person are correcting an administrative error, demonstrating transparency and adherence to SEC reporting requirements.
Negatives
- The initial erroneous filing indicates a potential administrative oversight in reporting.
- Maria Palasis forfeited 11,000 performance stock options (550,000 pre-split) for no value on February 14, 2025.
Risks
- Potential for administrative errors in SEC filings, though corrected in this instance, could lead to temporary misinformation for investors.
Future Outlook
No forward-looking statements or guidance are provided in this filing.
Management Comments
- On October 3, 2025, a Form 4 was inadvertently filed reporting the acquisition of 3,667 PSOs by the Reporting Person. In fact, the Reporting Person did not acquire the PSOs and this Form 4/A is being filed to correct the erroneously reported acquisition.
- As of the date hereof, the Reporting Person does not beneficially own any of the PSOs granted on March 21, 2024.
Industry Context
This filing is a routine compliance amendment within the biotechnology/pharmaceutical industry, reflecting standard corporate governance practices for executive compensation reporting. It does not provide insights into broader industry trends or competitive landscape.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Reporting Correction | An amendment (Form 4/A) was filed to correct an erroneous previous Form 4, ensuring accurate disclosure of executive beneficial ownership of securities. | 2025-10-08 | Enhances transparency and compliance with SEC regulations regarding insider trading and beneficial ownership reporting, reinforcing corporate governance standards. |
Stakeholder Impact
- Shareholders receive clarified and accurate information regarding executive beneficial ownership and compensation, which is crucial for informed investment decisions and maintaining trust in corporate disclosures.
Next Steps
- No specific future actions, events, or milestones are mentioned in this filing.
Key Dates
| Date | Description |
|---|---|
| 2024-03-21 | Performance Stock Option (PSO) for up to 11,000 shares granted to Maria Palasis under the Issuer's 2020 Incentive Award Plan. |
| 2025-02-14 | Performance Stock Options (PSOs) were forfeited in their entirety by Maria Palasis for no value. |
| 2025-10-01 | Date of earliest transaction erroneously reported in the original Form 4. |
| 2025-10-03 | Original Form 4 inadvertently filed, erroneously reporting PSO acquisition by Maria Palasis. |
| 2025-10-08 | Date of filing of this Form 4/A to correct the erroneously reported acquisition. |
Keywords
Lyra Therapeutics, LYRA, SEC Form 4/A, Beneficial Ownership, Stock Options, Executive Compensation, Maria Palasis, Amendment, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.